Singapore - English - HSA (Health Sciences Authority)

lotus international pte. ltd. - ixabepilone - injection, powder, lyophilized, for solution - 15 mg/vial - ixabepilone 15 mg/vial

Singapore - English - HSA (Health Sciences Authority)

lotus international pte. ltd. - ixabepilone - injection, powder, lyophilized, for solution - 45 mg/vial - ixabepilone 45 mg/vial

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - pembrolizumab -

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - mitoxantrone hydrochloride (unii: u6usw86rd0) (mitoxantrone - unii:bz114nvm5p) - mitoxantrone 2 mg in 1 ml - mitoxantrone injection, usp is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). mitoxantrone injection, usp is not indicated in the treatment of patients with primary progressive multiple sclerosis. the clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability.  mitoxantrone injection, usp in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. mi

Australia - English - Department of Health (Therapeutic Goods Administration)

emcure pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604.1 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid; nitrogen - malignant pleural mesothelioma pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

United States - English - NLM (National Library of Medicine)

loxo oncology, inc. - larotrectinib (unii: pf9462i9hx) (larotrectinib - unii:pf9462i9hx) - vitrakvi is indicated for the treatment of adult and pediatric patients with solid tumors that: this indication is approved under accelerated approval based on overall response rate and duration of response [see clinical studies (14)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. none. risk summary based on literature reports in human subjects with congenital mutations leading to changes in trk signaling, findings from animal studies, and its mechanism of action [see clinical pharmacology (12.1)] , vitrakvi can cause embryo-fetal harm when administered to a pregnant woman. there are no available data on vitrakvi use in pregnant women. administration of larotrectinib to pregnant rats and rabbits during the period of organogenesis resulted in malformations at maternal exposures that were approximately 11- and 0.7-times, respectively, those observed at the clinical dose of 100 mg twice daily (see data) . advise pregnant wo

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - crizotinib -

New Zealand - English - Medsafe (Medicines Safety Authority)

eisai new zealand limited - lenvatinib mesilate 12.25mg equivalent to lenvatinib 10mg - capsule - 10 mg - active: lenvatinib mesilate 12.25mg equivalent to lenvatinib 10mg excipient: calcium carbonate hyprolose as 25mg low-substituted hydroxypropyl cellulose + 3mg hydroxypropylcellulose hypromellose iron oxide black iron oxide red iron oxide yellow mannitol microcrystalline cellulose potassium hydroxide propylene glycol purified talc shellac titanium dioxide - lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine refractory differentiated thyroid cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

eisai new zealand limited - lenvatinib mesilate 4.9mg equivalent to lenvatinib 4mg - capsule - 4 mg - active: lenvatinib mesilate 4.9mg equivalent to lenvatinib 4mg excipient: calcium carbonate hyprolose as 25mg low-substituted hydroxypropyl cellulose + 3mg hydroxypropylcellulose hypromellose iron oxide black iron oxide red iron oxide yellow mannitol microcrystalline cellulose potassium hydroxide propylene glycol purified talc shellac titanium dioxide - lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine refractory differentiated thyroid cancer.

Canada - English - Health Canada

loxo oncology inc - selpercatinib - capsule - 40mg - selpercatinib 40mg - antineoplastic agents